Target antigen density governs the efficacy of anti-CD20-CD28-CD3 ζ chimeric antigen receptor-modified effector CD8+ T cells

Journal of Immunology

Volumn 194, Issue 3, 2015, Pages 911-920

  Watanabe, Keisuke ^a   Terakura, Seitaro ^a   Martens, Anton C ^b,c   Van Meerten, Tom ^d   Uchiyama, Susumu ^e   Imai, Misa ^f   Sakemura, Reona ^a   Goto, Tatsunori ^a   Hanajiri, Ryo ^a   Imahashi, Nobuhiko ^a   Shimada, Kazuyuki ^a,g   Tomita, Akihiro ^a   Kiyoi, Hitoshi ^a   Nishida, Tetsuya ^a   Naoe, Tomoki ^a,h   Murata, Makoto ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^d UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^e OSAKA UNIVERSITY   (Japan)

^f MEIJO UNIVERSITY   (Japan)

^g NAGOYA UNIVERSITY   (Japan)

^h NATIONAL HOSPITAL ORGANIZATION NAGOYA MEDICAL CENTER   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CD20 ANTIGEN; CD28 ANTIGEN; CD3 ANTIGEN; CHIMERIC ANTIGEN RECEPTOR; GAMMA INTERFERON; OFATUMUMAB; RITUXIMAB; CD3 ANTIGEN, ZETA CHAIN; CYTOKINE; LYMPHOCYTE ANTIGEN RECEPTOR; MEMBRANE ANTIGEN; MONOCLONAL ANTIBODY; PROTEIN BINDING; RECOMBINANT PROTEIN; T LYMPHOCYTE RECEPTOR;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANTIGEN BINDING; ANTIGEN DENSITY; ANTIGEN EXPRESSION; ANTIGEN FUNCTION; ANTIGEN LOCALIZATION; ANTIGEN STRUCTURE; ARTICLE; BINDING AFFINITY; CASE REPORT; CD20 CHIMERIC ANTIGEN RECEPTOR TRANSDUCED T CELL; CD8+ T LYMPHOCYTE; CELL DIVISION; CELL MEDIATED CYTOTOXICITY; CELL THERAPY; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; CYTOLYSIS; DOWN REGULATION; HUMAN; HUMAN CELL; LYMPHOMA; PRIMARY CELL CULTURE; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION; BIOSYNTHESIS; CYTOTOXICITY; GENE EXPRESSION; GENE ORDER; GENETIC TRANSDUCTION; GENETICS; IMMUNOLOGY; IMMUNOPHENOTYPING; INTRACELLULAR SPACE; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LYMPHOCYTE ACTIVATION; LYMPHOMA, B-CELL; METABOLISM; REPORTER GENE; T LYMPHOCYTE SUBPOPULATION; TUMOR CELL LINE;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIGENS, CD20; ANTIGENS, CD28; ANTIGENS, CD3; ANTIGENS, SURFACE; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; CYTOKINES; CYTOTOXICITY, IMMUNOLOGIC; GENE EXPRESSION; GENE ORDER; GENES, REPORTER; HUMANS; IMMUNOPHENOTYPING; INTRACELLULAR SPACE; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LYMPHOCYTE ACTIVATION; LYMPHOMA, B-CELL; PROTEIN BINDING; RECEPTORS, ANTIGEN, T-CELL; RECOMBINANT PROTEINS; SIGNAL TRANSDUCTION; T-CELL ANTIGEN RECEPTOR SPECIFICITY; T-LYMPHOCYTE SUBSETS; TRANSDUCTION, GENETIC;

EID: 84921473544     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1402346     Document Type: Article

References (47)

1. Porter, D. L., B. L. Levine, M. Kalos, A. Bagg, and C. H. June. 2011. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N. Engl. J. Med. 365: 725-733.
2. Grupp, S. A., M. Kalos, D. Barrett, R. Aplenc, D. L. Porter, S. R. Rheingold, D. T. Teachey, A. Chew, B. Hauck, J. F. Wright, et al. 2013. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N. Engl. J. Med. 368: 1509-1518.
3. Sadelain, M., R. Brentjens, and I. Riviere. 2013. The basic principles of chimeric antigen receptor design. Cancer Discov. 3: 388-398.
4. Jensen, M. C., and S. R. Riddell. 2014. Design and implementation of adoptive therapy with chimeric antigen receptor-modified T cells. Immunol. Rev. 257: 127-144.
5. Turtle, C. J., M. Hudecek, M. C. Jensen, and S. R. Riddell. 2012. Engineered T cells for anti-cancer therapy. Curr. Opin. Immunol. 24: 633-639.
6. Kowolik, C. M., M. S. Topp, S. Gonzalez, T. Pfeiffer, S. Olivares, N. Gonzalez, D. D. Smith, S. J. Forman, M. C. Jensen, and L. J. Cooper. 2006. CD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T cells. Cancer Res. 66: 10995-11004.
7. Imai, C., K. Mihara, M. Andreansky, I. C. Nicholson, C. H. Pui, T. L. Geiger, and D. Campana. 2004. Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia. Leukemia 18: 676-684.
8. + T cell-mediated tumor eradication. Mol. Ther. 18: 413-420.
9. Kochenderfer, J. N., M. E. Dudley, S. A. Feldman, W. H. Wilson, D. E. Spaner, I. Maric, M. Stetler-Stevenson, G. Q. Phan, M. S. Hughes, R. M. Sherry, et al. 2012. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood 119: 2709-2720.
10. Morgan, R. A., J. C. Yang, M. Kitano, M. E. Dudley, C. M. Laurencot, and S. A. Rosenberg. 2010. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol. Ther. 18: 843-851.
11. Hudis, C. A. 2007. Trastuzumab - mechanism of action and use in clinical practice. N. Engl. J. Med. 357: 39-51.
12. Ménard, S., P. Casalini, M. Campiglio, S. M. Pupa, and E. Tagliabue. 2004. Role of HER2/neu in tumor progression and therapy. Cell. Mol. Life Sci. 61: 2965-2978.
13. Purbhoo, M. A., D. H. Sutton, J. E. Brewer, R. E. Mullings, M. E. Hill, T. M. Mahon, J. Karbach, E. Jäger, B. J. Cameron, N. Lissin, et al. 2006. Quantifying and imaging NY-ESO-1/LAGE-1-derived epitopes on tumor cells using high affinity T cell receptors. J. Immunol. 176: 7308-7316.
14. Liddy, N., G. Bossi, K. J. Adams, A. Lissina, T. M. Mahon, N. J. Hassan, J. Gavarret, F. C. Bianchi, N. J. Pumphrey, K. Ladell, et al. 2012. Monoclonal TCR-redirected tumor cell killing. Nat. Med. 18: 980-987.
15. Sadelain, M., R. Brentjens, and I. Rivière. 2009. The promise and potential pitfalls of chimeric antigen receptors. Curr. Opin. Immunol. 21: 215-223.
16. Thomas, D. A., S. O'Brien, S. Faderl, G. Garcia-Manero, A. Ferrajoli, W. Wierda, F. Ravandi, S. Verstovsek, J. L. Jorgensen, C. Bueso-Ramos, et al. 2010. Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia. J. Clin. Oncol. 28: 3880-3889.
17. Jaglowski, S. M., L. Alinari, R. Lapalombella, N. Muthusamy, and J. C. Byrd. 2010. The clinical application of monoclonal antibodies in chronic lymphocytic leukemia. Blood 116: 3705-3714.
18. Abramson, J. S., and M. A. Shipp. 2005. Advances in the biology and therapy of diffuse large B-cell lymphoma: moving toward a molecularly targeted approach. Blood 106: 1164-1174.
19. Jazirehi, A. R., and B. Bonavida. 2005. Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin's lymphoma: implications in chemosensitization and therapeutic intervention. Oncogene 24: 2121-2143.
20. Hiraga, J., A. Tomita, T. Sugimoto, K. Shimada, M. Ito, S. Nakamura, H. Kiyoi, T. Kinoshita, and T. Naoe. 2009. Down-regulation of CD20 expression in B-cell lymphoma cells after treatment with rituximab-containing combination chemotherapies: its prevalence and clinical significance. Blood 113: 4885-4893.
21. Jilani, I., S. O'Brien, T. Manshuri, D. A. Thomas, V. A. Thomazy, M. Imam, S. Naeem, S. Verstovsek, H. Kantarjian, F. Giles, et al. 2003. Transient down-modulation of CD20 by rituximab in patients with chronic lymphocytic leukemia. Blood 102: 3514-3520.
22. Tsai, P. C., F. J. Hernandez-Ilizaliturri, N. Bangia, S. H. Olejniczak, and M. S. Czuczman. 2012. Regulation of CD20 in rituximab-resistant cell lines and B-cell non-Hodgkin lymphoma. Clin. Cancer Res. 18: 1039-1050.
23. Johnson, N. A., S. Leach, B. Woolcock, R. J. deLeeuw, A. Bashashati, L. H. Sehn, J. M. Connors, M. Chhanabhai, A. Brooks-Wilson, and R. D. Gascoyne. 2009. CD20 mutations involving the rituximab epitope are rare in diffuse large B-cell lymphomas and are not a significant cause of R-CHOP failure. Haematologica 94: 423-427.
24. Shimada, K., A. Tomita, S. Saito, and H. Kiyoi. 2014. Efficacy of ofatumumab against rituximab-resistant B-CLL/SLL cells with low CD20 protein expression. Br. J. Haematol. 166: 455-457.
25. Uchiyama, S., Y. Suzuki, K. Otake, M. Yokoyama, M. Ohta, S. Aikawa, M. Komatsu, T. Sawada, Y. Kagami, Y. Morishima, and K. Fukui. 2010. Development of novel humanized anti-CD20 antibodies based on affinity constant and epitope. Cancer Sci. 101: 201-209.
26. Tomita, A., J. Hiraga, H. Kiyoi, M. Ninomiya, T. Sugimoto, M. Ito, T. Kinoshita, and T. Naoe. 2007. Epigenetic regulation of CD20 protein expression in a novel B-cell lymphoma cell line, RRBL1, established from a patient treated repeatedly with rituximab-containing chemotherapy. Int. J. Hematol. 86: 49-57.
27. Sonoki, T., Y. Li, S. Miyanishi, H. Nakamine, N. Hanaoka, H. Matsuoka, I. Mori, and H. Nakakuma. 2009. Establishment of a novel CD20 negative mature B-cell line, WILL2, from a CD20 positive diffuse large B-cell lymphoma patient treated with rituximab. Int. J. Hematol. 89: 400-402.
28. van Meerten, T., R. S. van Rijn, S. Hol, A. Hagenbeek, and S. B. Ebeling. 2006. Complement-induced cell death by rituximab depends on CD20 expression level and acts complementary to antibody-dependent cellular cytotoxicity. Clin. Cancer Res. 12: 4027-4035.
29. + T cells derived from virus-specific central memory T cells. Blood 119: 72-82.
30. Lenkei, R., J. W. Gratama, G. Rothe, G. Schmitz, J. L. D'hautcourt, A. Arekrans, F. Mandy, and G. Marti. 1998. Performance of calibration standards for antigen quantitation with flow cytometry. Cytometry 33: 188-196.
31. Kumar, A., E. T. Petri, B. Halmos, and T. J. Boggon. 2008. Structure and clinical relevance of the epidermal growth factor receptor in human cancer. J. Clin. Oncol. 26: 1742-1751.
32. Wang, X., W. C. Chang, C. W. Wong, D. Colcher, M. Sherman, J. R. Ostberg, S. J. Forman, S. R. Riddell, and M. C. Jensen. 2011. A transgene-encoded cell surface polypeptide for selection, in vivo tracking, and ablation of engineered cells. Blood 118: 1255-1263.
33. Szymczak-Workman, A. L., K. M. Vignali, and D. A. Vignali. 2012. Design and construction of 2A peptide-linked multicistronic vectors. Cold Spring Harb. Protoc. 2012(2): 199-204.
34. Andris-Widhopf, J., P. Steinberger, R. Fuller, C. Rader, and C. F. Barbas, 3rd. 2011. Generation of human scFv antibody libraries: PCR amplification and assembly of light- and heavy-chain coding sequences. Cold Spring Harb. Protoc. 2011(9).
35. Weijtens, M. E., R. A. Willemsen, B. A. van Krimpen, and R. L. Bolhuis. 1998. Chimeric scFv/gamma receptor-mediated T-cell lysis of tumor cells is coregulated by adhesion and accessory molecules. Int. J. Cancer 77: 181-187.
36. Faroudi, M., C. Utzny, M. Salio, V. Cerundolo, M. Guiraud, S. Muller, and S. Valitutti. 2003. Lytic versus stimulatory synapse in cytotoxic T lymphocyte/target cell interaction: manifestation of a dual activation threshold. Proc. Natl. Acad. Sci. USA 100: 14145-14150.
37. Oki, Y., J. R. Westin, F Vega, H. Chuang, N. Fowler, S. Neelapu, F B. Hagemeister, P. McLaughlin, L. W. Kwak, J. E. Romaguera, et al. 2013. Prospective phase II study of rituximab with alternating cycles of hyper-CVAD and high-dose methotrexate with cytarabine for young patients with high-risk diffuse large B-cell lymphoma. Br. J. Haematol. 163: 611-620.
38. Hallek, M., B. D. Cheson, D. Catovsky, F Caligaris-Cappio, G. Dighiero, H. Döhner, P. Hillmen, M. J. Keating, E. Montserrat, K. R. Rai, and T. J. Kipps, International Workshop on Chronic Lymphocytic Leukemia. 2008. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 111: 5446-5456.
39. Prevodnik, V. K., J. Lavrencak, M. Horvat, and B. J. Novakovic. 2011. The predictive significance of CD20 expression in B-cell lymphomas. Diagn. Pathol. 6: 33.
40. Wierda, W. G, S. Padmanabhan, G. W. Chan, I. V. Gupta, S. Lisby, and A. Osterborg, Hx-CD20-406 Study Investigators. 2011. Ofatumumab is active in patients with fludarabine-refractory CLL irrespective of prior rituximab: results from the phase 2 international study. Blood 118: 5126-5129.
41. Scott, A. M., J. D. Wolchok, and L. J. Old. 2012. Antibody therapy of cancer. Nat. Rev. Cancer 12: 278-287.
42. Turatti, F., M. Figini, E. Balladore, P. Alberti, P. Casalini, J. D. Marks, S. Canevari, and D. Mezzanzanica. 2007. Redirected activity of human antitumor chimeric immune receptors is governed by antigen and receptor expression levels and affinity of interaction. J. Immunother. 30: 684-693.
43. Hudecek, M., M. T. Lupo-Stanghellini, P. L. Kosasih, D. Sommermeyer, M. C. Jensen, C. Rader, and S. R. Riddell. 2013. Receptor affinity and extracellular domain modifications affect tumor recognition by ROR1-specific chimeric antigen receptor T cells. Clin. Cancer Res. 19: 3153-3164.
44. Haso, W., D. W. Lee, N. N. Shah, M. Stetler-Stevenson, C. M. Yuan, I. H. Pastan, D. S. Dimitrov, R. A. Morgan, D. J. FitzGerald, D. M. Barrett, et al. 2013. Anti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia. Blood 121: 1165-1174.
45. Long, A. H., W. M. Haso, and R. J. Orentas. 2013. Lessons learned from a highly-active CD22-specific chimeric antigen receptor. OncoImmunology 2: e23621.
46. Casucci, M., B. Nicolis di Robilant, L. Falcone, B. Camisa, M. Norelli, P. Genovese, B. Gentner, F. Gullotta, M. Ponzoni, M. Bernardi, et al. 2013. CD44v6-targeted T cells mediate potent antitumor effects against acute myeloid leukemia and multiple myeloma. Blood 122: 3461-3472.
47. Tang, Y., J. Lou, R. K. Alpaugh, M. K. Robinson, J. D. Marks, and L. M. Weiner. 2007. Regulation of antibody-dependent cellular cytotoxicity by IgG intrinsic and apparent affinity for target antigen. J. Immunol. 179: 2815-2823.